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Abstract
Flecainide is a class 1C antiarrhythmic drug especially used for the management of
supraventricular arrhythmia. In overdose cases, flecainide can induce life treating ventricular
arrhythmias and cardiogenic shock. We report the case of a 72-year-old woman admitted to
our intensive care unit for a regular monomorphic wide complex tachycardia (QRS duration
240 ms, right bundle branch block and superior axis morphology) without apparent P waves.
Clinical examination showed slight left congestive heart failure signs without cardiogenic
shock. An intravenous bolus of 10 mg adenosine 5’-triphosphate (ATP) was ineffective to stop
the tachycardia. The diagnosis of ventricular tachycardia induced by flecainide overdose was
considered. 500 mL of intravenous 84‰ sodium bicarbonate was administrated. The patient’s
QRS narrowed immediately and 12-lead ECG showed sinus rhythm. Blood samples confirmed the
flecainide overdose and the clinical status progressively improved. (Cardiol J 2013; 20, 2: 203–205)
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Introduction
Flecainide is a class 1C antiarrhythmic drug
used especially for the management of supra-ven-
tricular like atrial fibrillation (AF) [1]. It causes rate-
dependent slowing of the rapid sodium channel
slowing phase 0 of depolarisation and in high doses
inhibits the slow calcium channel [2]. Flecainide
also slows conduction in all cardiac fibers, increas-
ing conduction times in the atria, ventricles, atrio-
ventricular node and His-Purkinje system. Fleca-
inide can also cause myocardial depression. In over-
dose cases, flecainide induced life treating
ventricular arrhythmia and cardiogenic shock re-
quiring sometimes extracorporeal membrane oxy-
genation [3, 4].
Case report
A 72-year-old woman was admitted to our in-
tensive care unit for breathlessness in a context of
a regular tachycardia with wide QRS complex. Her
medical history included hypertension, paroxysmal
AF and a significant psychiatric history. She was
treated with flecainide (100 mg twice daily), irbe-
sartan (300 mg daily) and haloperidol (1 mg twice
daily). Of note, she had no beta-blocker therapy.
Questioning did not find any voluntary drug intoxi-
cation. Her general practitioner performed three
months ago a 12-lead ECG. It showed sinus rhythm
with QTc interval of 400 ms and QRS duration of
100 ms. Before her admission to our intensive care
unit, she was given 150 mg of intravenous amio-
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darone in the emergency room. Clinical examination
showed slight left congestive heart failure signs with-
out cardiogenic shock (blood pressure 100/60 mm
Hg, oxygen saturation 95%). The 12-lead ECG
showed a regular monomorphic wide complex tachy-
cardia at 150 bpm without apparent P wave (Fig. 1).
QRS duration was around 240 ms with a left bundle
branch block and inferior axis morphology. Transtho-
racic echocardiography showed a mild left ventricu-
lar hypertrophy with a moderate systolic dysfunction
(left ventricular ejection fraction 35%), a lack of atrial
systole on trans-mitral flow and no valvular disease.
An intravenous bolus of 10 mg adenosine 5’-tri-
phosphate (ATP) was used as a diagnostic tool to
identify the mechanism of the tachycardia. This ad-
ministration was ineffective to slow or stop the ta-
chycardia. The diagnosis of ventricular tachycardia
induced by flecainide overdose was considered and
500 mL of intravenous 84‰ sodium bicarbonate was
administrated. The patient’s QRS narrowed imme-
diately following sodium bicarbonate infusion and
12-lead ECG showed sinus rhythm without evidence
of accessory pathway (Fig. 2). Blood samples per-
formed before sodium bicarbonate infusion demon-
strated mild metabolic acidosis (pH 7.36, normal
7.37–7.45, arterial lactate 1.60 mmol/L, normal
< 1.20), mild renal failure (estimated glomerular fil-
tration rate with MDRD at 42 mL/min), BNP rise
(1019 ng/L, normal value < 100) and a flecainide
level at 2.13 mg/L (normal therapeutic range 0.2–
–1 mg/L). Otherwise, troponin I level, blood cells
count and serum electrolytes, especially kaliemia,
were unremarkable. Clinical status progressively
improved. On day 7, transthoracic echocardiography
showed a left ventricular ejection fraction improve-
ment up to 50% and the patient was discharged from
hospital with a treatment associating amiodarone
and irbesartan. One month later, the patient was ad-
mitted to our hospital for a check-up. The Holter
ECG showed a permanent sinus rhythm without
paroxysmal arrhythmias. The coronary angiogram
ruled out any coronary artery stenosis. An electro-
physiological study demonstrated no inducible ven-
tricular or supraventricular arrhythmias.
Figure 1. 12-lead ECG displays monomorphic wide complex (QRS duration 240 ms, left bundle branch block inferior
axis morphology) tachycardia at 150 bpm without apparent P waves.
Figure 2. 12-lead ECG demonstrates a sinus rhythm after administration of 500 mL of intravenous 84‰ sodium
bicarbonate.
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Discussion
Flecainide, a class 1C anti-arrhythmic agent,
depresses the rate of depolarization of cardiac ac-
tion potentials producing a membrane stabilizing
action. It is a very effective anti-arrhythmic agent
against supraventricular arrhythmias, nevertheless
flecainide is contraindicated in patients with struc-
tural heart disease because it increased mortality
[1]. The proarrhythmic effect of flecainide may be
related to promoting a reentry in ventricular tissue.
The phenomenon is due to a rate-dependent block-
ade of rapid sodium channels slowing phase 0 of
depolarization and an inhibition of the slow calcium
channel [2]. In cases of overdose, the mortality with
class Ic agents has been reported to approach 22%.
Conduction disturbances began with widening of
QRS complex which can rapidly progress to ven-
tricular tachycardia, electromechanical dissociation
and asystole. The markers of poor prognosis for
overdose with membrane stabilizing action drugs
are: ingested dose, heart rate > 100 bpm, QRS du-
ration > 100 ms and QT elongation [5]. In the
present report, predisposing factors of flecainide
toxicity were left ventricular hypertrophy, metabo-
lic acidosis, renal failure (flecainide is mainly excret-
ed in urine), mild heart failure and a likely drug in-
teraction with haloperidol. Of note, we did not found
predisposing genetic factors in our patient. Al-
though there are only few successfully treated cas-
es reported [6, 7], hypertonic sodium bicarbonate
is considered as a specific antidote to treat flecain-
ide overdose. Hypertonic sodium bicarbonate in-
creases extra cellular concentration of sodium dis-
placing flecainide from its receptors sites. Because
flecainide is a weak acid, alkalinization may also
decrease the active-ionized fraction of flecainide
necessary for sodium channels blockade [8]. In our
case, sodium bicarbonate infusion significantly re-
duced QRS duration in few minutes and improved
hemodynamic status. This case report tends to con-
firm the therapeutic efficiency of sodium bicarbo-
nate in a case of moderate flecainide overdose.
ATP can be used as an effective diagnosis tool
in identifying the mechanism of wide QRS tachy-
cardia. ATP frequently terminated supraventricu-
lar tachycardia, but it had no effect on preexcited
AF or atrial flutter. ATP can also terminated ven-
tricular tachycardia due to triggered-activity or au-
tomacity, while ventricular tachycardia related to
reentry are insensitive to this drug [9]. Our report
supports this data. During flecainide overdose, the
mechanism of ventricular arrhythmias is also a ven-
tricular reentry and thus ATP cannot terminate the
tachycardia. Hence, ATP is normally considered an
antiarrhythmic agent.
Conclusions
We illustrated with our report that ATP is not
an effective antiarrythmic agent to terminate a ven-
tricular arrhythmias due to flecainide toxicity. In
this clinical setting, sodium bicarbonate should be
preferred.
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